Brii Biosciences has announced a strategic decision to end the manufacturing and further development of the amubarvimab/romlusevimab combination treatment regimen for COVID-19. According to the company’s recent 2022 financial report, the antibody cocktail had been commercially available in China from July 2022 following an emergency use authorization (EUA) and had generated RMB 51.6 million (USD 7.5 million) in sales. However, the program will now be discontinued, with manufacturing ceasing and applications for an EUA approval with the US FDA and full market approval with the National Medical Products Administration (NMPA) being withdrawn.
Resource Reallocation to Other Pipeline Developments
Brii Biosciences is moving to free up resources for its other pipeline developments, which include both in-licensed drugs and in-house discoveries. This strategic redirection reflects the company’s commitment to prioritizing other therapeutic areas with high unmet medical needs.
Advanced Hepatitis B Virus Program and Other Therapeutic Targets
The most advanced program in Brii’s pipeline is for hepatitis B virus, where Brii is co-developing three drug candidates with Vir Biotechnology (Nasdaq: VIR) and VBI Vaccines (Nasdaq: VBIV). Other diseases being targeted by Brii include HIV, postpartum depression, major depressive disorder, and a program focused on multidrug- and extensively drug-resistant (MDR/XDR) anti-bacterials.-Fineline Info & Tech
